Montelukast oral film may help in mild to moderate Alzheimer’s

The use of Montelukast oral film, an experimental therapy being repurposed by Intelgenx to treat mild to moderate Alzheimer’s disease, led to significant improvements in patients’ cognition versus a placebo in a Phase 2 clinical trial. That’s according to the findings of a top-line analysis of efficacy data…

COYA 301 therapy shows ‘encouraging results’ for Alzheimer’s

“Encouraging results” were reported in eight Alzheimer’s disease patients with dementia who were treated with COYA 301, an experimental therapy being evaluated in a small clinical trial, according to Coya Therapeutics, its developer. “Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed…

COSMOS-Mind: Daily Multivitamin Improves Cognition in Older Adults

Three years of a daily multivitamin-mineral supplement improved memory, and cognitive and executive function in older adults, according to data from the COSMOS-Mind study. Three years of administering cocoa extract every day had no effect on cognitive function, however. “This is the first positive, large-scale, long-term study to show that…

Cancer Medication Improves Cognition in Alzheimer’s Mouse Model

Trametinib, an oral medication approved to treat certain cancers, improved cognition and neuronal health in a mouse model of Alzheimer’s disease, according to a new study. Data suggest the treatment helped to clear toxic protein aggregates from nerve cells. The study, “MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation…

HT-ALZ Leads to Cognitive Improvements in Diseased Mice

Chronic treatment with HT-ALZ, Hoth Therapeutics‘ investigational oral therapy for Alzheimer’s disease, led to significant cognitive improvements in a mouse model of the neurodegenerative condition. The data were collected as part of Hoth’s ongoing sponsored research agreement with investigators at Washington University in St. Louis, Missouri, led by…

1st Patient Dosed With Bryostatin as Developer Seeks Best Regimen

The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…